Three years after receiving a €331 million ($373 million) fine from European antitrust authorities over a pay-for-delay deal on the blood pressure drug perindopril, Servier is fighting in a European court hearing to cut its punishment.
During the first of a four-day hearing on the case, an attorney for Servier argued that competition commissioners were biased in their review and committed legal and procedural mistakes, according to Reuters.
In 2014, European authorities handed out €427.7 million ($482 million) in fines to six companies over pay-for-delay arrangements on the Servier bestseller that delayed competition and hurt consumers. Servier took the biggest hit at €331 million, while Mylan, Teva, Lupin, Krka and Unichem were also involved.
At the time of the fine, authorities said the companies conducted numerous deals to protect perindopril from generic competition. A lawyer for the government maintained this week that the reviewers looked at the case in a “neutral manner,” according to the news service.
Servier’s hearing comes shortly after the EU’s competition authority announced a probe into cancer-drug pricing from South Africa’s Aspen Pharmacare. In that effort, the government is hoping to learn whether Aspen “abused a dominant market position in breach of EU antitrust rules.”
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI